Weakly Supervised Learning using Attention gates for colon cancer histopathological image segmentation.

Recently, Artificial Intelligence namely Deep Learning methods have revolutionized a wide range of domains and applications. Besides, Digital Pathology has so far played a major role in the diagnosis and the prognosis of tumors. However, the characteristics of the Whole Slide Images namely the gigapixel size, high resolution and the shortage of richly labeled samples have hindered the efficiency of classical Machine Learning methods. That goes without saying that traditional methods are poor in generalization to different tasks and data contents. Regarding the success of Deep learning when dealing with Large Scale applications, we have resorted to the use of such models for histopathological image segmentation tasks. First, we review and compare the classical UNet and Att-UNet models for colon cancer WSI segmentation in a sparsely annotated data scenario. Then, we introduce novel enhanced models of the Att-UNet where different schemes are proposed for the skip connections and spatial attention gates positions in the network. In fact, spatial attention gates assist the training process and enable the model to avoid irrelevant feature learning. Alternating the presence of such modules namely in our Alter-AttUNet model adds robustness and ensures better image segmentation results. In order to cope with the lack of richly annotated data in our AiCOLO colon cancer dataset, we suggest the use of a multi-step training strategy that also deals with the WSI sparse annotations and unbalanced class issues. All proposed methods outperform state-of-the-art approaches but Alter-AttUNet generates the best compromise between accurate results and light network. The model achieves 95.88% accuracy with our sparse AiCOLO colon cancer datasets. Finally, to evaluate and validate our proposed architectures we resort to publicly available WSI data: the NCT-CRC-HE-100K, the CRC-5000 and the Warwick colon cancer histopathological dataset. Respective accuracies of 99.65%, 99.73% and 79.03% were reached. A comparison with state-of-art approaches is established to view and compare the key solutions for histopathological image segmentation.

Deep learning for colon cancer histopathological images analysis.

Nowadays, digital pathology plays a major role in the diagnosis and prognosis of tumours. Unfortunately, existing methods remain limited when faced with the high resolution and size of Whole Slide Images (WSIs) coupled with the lack of richly annotated datasets. Regarding the ability of the Deep Learning (DL) methods to cope with the large scale applications, such models seem like an appealing solution for tissue classification and segmentation in histopathological images. This paper focuses on the use of DL architectures to classify and highlight colon cancer regions in a sparsely annotated histopathological data context. First, we review and compare state-of-the-art Convolutional Neural networks (CNN) including the AlexNet, vgg, ResNet, DenseNet and Inception models. To cope with the shortage of rich WSI datasets, we have resorted to the use of transfer learning techniques. This strategy comes with the hallmark of relying on a large size computer vision dataset (ImageNet) to train the network and generate a rich collection of learnt features. The testing and evaluation of such models on our AiCOLO colon cancer dataset ensure accurate patch-level classification results reaching up to 96.98% accuracy rate with ResNet. The CNN models have also been tested and evaluated with the CRC-5000, nct-crc-he-100k and merged datasets. ResNet respectively achieves 96.77%, 99.76% and 99.98% for the three publicly available datasets. Then, we present a pixel-wise segmentation strategy for colon cancer WSIs through the use of both UNet and SegNet models. We introduce a multi-step training strategy as a remedy for the sparse annotation of histopathological images. UNet and SegNet are used and tested in different training scenarios including data augmentation and transfer learning and ensure up to 76.18% and 81.22% accuracy rates. Besides, we test our training strategy and models on the CRC-5000, nct-crc-he-100k and Warwick datasets. Respective accuracy rates of 98.66%, 99.12% and 78.39% were achieved by SegNet. Finally, we analyze the existing models to discover the most suitable network and the most effective training strategy for our colon tumour segmentation case study.1.

Diagnosis of hepatocellular carcinoma in cirrhotic patients: a proof-of-concept study using serum micro-Raman spectroscopy.

Hepatocellular carcinoma (HCC) is the third most common cause of cancer death worldwide. The development of novel diagnostic methods is needed to detect tumours at an early stage when patients are eligible for curative treatments. The purpose of this proof-of-concept study was to determine if micro-Raman spectroscopy applied to the sera of cirrhotic patients may be an alternative method for rapidly discriminating patients with and without HCC. Serum samples were collected from 2 groups of patients: cirrhotic patients with HCC (n = 37) and without HCC (n = 34). Two different approaches were used, dried serum drops and freeze-dried serum, and micro-Raman spectra were acquired in the point-mode with a 785 nm laser excitation in the spectral range of 600-1800 cm(-1). Spectra were quality-tested and pre-processed (smoothing, baseline subtraction, vector normalization). Using principal component analysis, the 2 classes, corresponding to cirrhotic patients with and without HCC, could not be differentiated. In contrast, the support vector machine method using the leave-one-out cross validation procedure was able to correctly classify the two groups of patients with an overall rate of accuracy of 84.5% to 90.2% for dried serum drops and 86% to 91.5% for freeze-dried serum. These results are promising and support the concept that serum micro-Raman spectroscopy may become a useful diagnostic tool to detect biomarkers in the field of cancer, as described here for distinguishing between cirrhotic patients with and without HCC.